Equities

Natural Alternatives International Inc

Natural Alternatives International Inc

Actions
Consumer Staples Food Producers
  • Price (USD)6.74
  • Today's Change0.31 / 4.82%
  • Shares traded885.00
  • 1 Year change+5.97%
  • Beta0.5430
Data delayed at least 15 minutes, as of Sep 19 2024 15:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. The Company operates through two segments: Private-label contract manufacturing, and Royalty, licensing, and raw material. The Private-label contract manufacturing segment primarily provides manufacturing services to companies that market and distribute nutritional supplements and other health care products. Royalty, licensing, and raw material segment associated with the sale and license of beta-alanine under the Company’s CarnoSyn and SR CarnoSyn trademarks. The Company provides private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal and other nutritional supplements as well as other health care products. It private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores.

  • Revenue in USD (TTM)120.20m
  • Net income in USD-3.31m
  • Incorporated1989
  • Employees317.00
  • Location
    Natural Alternatives International Inc1535 Faraday AvenueCARLSBAD 92008United StatesUSA
  • Phone+1 (760) 736-7700
  • Fax+1 (760) 744-9589
  • Websitehttps://www.nai-online.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioXcel Therapeutics Inc2.40m-107.83m25.96m74.00------10.80-3.56-3.560.074-1.840.02340.59413.8732,472.97-104.93-74.57-150.29-84.0643.07---4,487.39-32,300.742.25-10.103.59--268.00---8.02---43.26--
KALA BIO Inc0.00-38.72m26.72m43.00--1.94-----13.95-13.950.002.980.00----0.00-60.45-57.83-78.16-69.32--57.06---1,553.61---11.360.7174---100.00--5.85---17.31--
Acasti Pharma Inc0.00-11.45m27.58m32.00--0.4646-----1.22-1.220.005.850.00-------16.04-31.68-16.57-33.95-------56,271.43---37.800.00------69.71---47.16--
Dare Bioscience Inc2.84m-7.20m27.60m23.00--10.33--9.72-1.07-1.070.35790.31260.1213--3.85123,462.20-30.76-109.51-191.39-246.260.8477---253.60-1,104.55----0.00---71.92--2.54--121.37--
Incannex Healthcare Inc-100.00bn-100.00bn29.21m----2.07----------0.8907-----------54.94---59.47-------1,033.07----0.00--61.923.38-24.35--54.12--
Equillium Inc42.62m-8.32m30.11m45.00--1.34--0.7064-0.2377-0.23771.200.63330.8388--8.85968,704.60-16.37-46.81-29.58-57.36-----19.52-328.35----0.00--128.97--78.64--7.48--
Ocuphire Pharma Inc16.45m-14.11m34.84m14.00--0.8503--2.12-0.5507-0.55070.68711.560.3726--6.531,174,929.00-31.95-58.31-36.01-65.94-----85.75-137.92---10.800.00---52.20---155.83------
Eyenovia Inc31.41k-37.28m38.49m57.00------1,225.34-0.7897-0.78970.0007-0.04250.0013--0.0418551.05-154.24-80.31-262.28-117.70-1,489.11---118,693.60-680.950.267-40.921.20------2.68--152.20--
Natural Alternatives International, Inc.120.20m-3.31m39.87m317.00--0.474129.710.3317-0.5646-0.564620.5313.560.80913.6312.77379,183.00-2.234.90-2.565.938.8515.98-2.753.802.44-2.710.09960.00-9.913.06-76.46-20.7427.08--
Fortress Biotech Inc82.62m-49.54m43.80m186.00--2.43--0.5302-3.71-3.716.050.79150.50632.366.07444,215.10-65.90-52.50-113.69-99.4668.7763.17-130.17-236.941.24-13.401.26--11.5825.7527.42---9.37--
Aadi Bioscience Inc23.82m-65.44m46.03m70.00--0.5842--1.93-2.43-2.430.88293.200.18840.63934.96267,606.80-51.76-50.25-60.12-56.1587.18---274.77-473.973.92--0.00--60.063.85-8.68--153.54--
Immix Biopharma Inc0.00-19.02m48.86m14.00--2.04-----0.8411-0.84110.000.8710.00----0.00-86.64---100.82--------------0.00-------87.44------
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Lexaria Bioscience Corp411.01k-4.85m50.91m5.00--5.03--123.86-0.4455-0.44550.04080.64030.0539--2.1682,202.00-63.85-95.67-65.93-96.5898.8376.98-1,185.15-1,612.76---64.960.00---11.43-12.198.31------
Data as of Sep 19 2024. Currency figures normalised to Natural Alternatives International Inc's reporting currency: US Dollar USD

Institutional shareholders

29.01%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 30 Jun 2024416.09k6.71%
Caldwell Sutter Capital, Inc. (Investment Management)as of 30 Jun 2024412.18k6.65%
Renaissance Technologies LLCas of 30 Jun 2024328.86k5.30%
The Vanguard Group, Inc.as of 30 Jun 2024240.24k3.87%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024174.84k2.82%
Bridgeway Capital Management LLCas of 30 Jun 2024124.86k2.01%
Geode Capital Management LLCas of 30 Jun 202442.15k0.68%
Empowered Funds LLCas of 30 Jun 202422.85k0.37%
Liberty Wealth Management LLCas of 31 Mar 202418.55k0.30%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202418.43k0.30%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.